Data protection Impressum

Personalized Medicine

From clinical research to international leadership, Incyte’s steady growth in Western Switzerland showcases the region’s strength in biopharmaceutical innovation.

Why Switzerland

Incyte, a key player in Western Switzerland’s biopharmaceutical innovation landscape

A new privately funded health innovation campus will take shape in Meyrin, combining clinical care, research, and industry in one integrated ecosystem.

Campus Santé, a landmark investment in Geneva’s future of healthcare and research

7 April 2025

The 10th edition of BioInnovation Day gathered more than 250 life sciences stakeholders at Campus Biotech in Geneva. Two standout projects, Artiria Medical and Reverso Therapeutics, were honoured for their innovative contributions to stroke treatment and cardiovascular medicine.

Artiria Medical and Reverso Therapeutics awarded at BioInnovation Day 2025

4 April 2025

The Foundation for Technological Innovation (FIT) has awarded funding to promising Western Switzerland start-ups PeriVision, Bioscibex, and Carewell, to accelerate their development in healthtech and biotechnology.

Western Switzerland innovators PeriVision, Bioscibex and Carewell receive support from FIT

17 March 2025

Vaud-based biopharma Oculis has successfully completed an oversubscribed USD 100 million offering, further strengthening its pipeline of innovative ophthalmic and neuro-ophthalmic treatments.

Oculis secures USD 100 million to advance its neuroprotective treatment pipeline

17 February 2025

The University Hospitals of Geneva (HUG) have introduced Switzerland’s first AI-driven medical chatbot, “confIAnce”, providing reliable, verified general medical information. This innovation represents a major step in integrating artificial intelligence into Swiss healthcare.

HUG pioneers AI-powered healthcare with Switzerland’s first medical chatbot

10 February 2025

The Lausanne University Hospital (CHUV) has secured market authorization from Swissmedic to produce a fecal microbiota transplant (FMT) medication, making it the first accredited center in Switzerland to manufacture this treatment under strict pharmaceutical standards. This breakthrough provides an effective solution for patients suffering from recurrent Clostridioides difficile infections, a debilitating condition characterized by repeated digestive blowouts and severe discomfort.

CHUV becomes first Swiss hospital to produce gut-balancing medication

29 January 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

Fribourg-based digital health start-up Neuria, a spin-off from the University of Fribourg, is set to launch its patented brain recalibration platform in Switzerland and the US.

Fribourg’s Neuria prepares to launch its brain recalibration platform

13 January 2025

1 2 3 4 5 … 17